UPLC–MS/MS study of the effect of dandelion root extract on the plasma levels of the selected irreversible tyrosine kinase inhibitors dasatinib, imatinib and nilotinib in rats: Potential risk of pharmacokinetic interactions

Biomedical Chromatography - Tập 33 Số 12 - 2019
Nourah Z. Alzoman1, Hadir M. Maher1,2, Shereen M. Shehata1, Norah O. Abanmy3
1College of Pharmacy, Department of Pharmaceutical Chemistry, King Saud University, Riyadh, Saudi Arabia
2Faculty of Pharmacy, Department of Pharmaceutical Analytical Chemistry, University of Alexandria, Alexandria, Egypt
3College of Pharmacy, Department of Clinical Pharmacy King Saud University Riyadh Saudi Arabia

Tóm tắt

AbstractTyrosine kinase inhibitor treatments for chronic myeloid leukaemia based on nilotinib (NIL), dasatinib (DAS) and imatinib (IMA) have improved patient quality of life and have turned chronic myeloid leukemia from a fatal disease into a chronic disease. Dandelion is a rich source of phenolic compounds with strong biological properties, and the effects of using this plant in the treatment of different illnesses can be linked to the presence of various polyphenols found in the different parts of the plant. Thus, dandelion can potentially be used as a nutraceutical (dietary antioxidant) to prevent different disorders associated with oxidative stress, i.e. cardiovascular disorders, cancer and inflammatory processes. Mutual interference between a drug and a food constituent may result in altered pharmacokinetics of the drug and undesired or even dangerous clinical situations. In the present study, a bioanalytical ultra performance liquid chromatography–tandem mass spectrometer (UPLC–MS/MS) method was developed and validated for the quantification of DAS, IMA and NIL in rat plasma. Sample preparation was carried out using solid‐phase extraction with C18 cartridges with a good extraction recovery of ≥94.37% for the three drugs. The method was fully validated as per the US Food and Drug Administration guidelines.

Từ khóa


Tài liệu tham khảo

10.1016/j.jchromb.2013.01.037

10.1016/j.cofs.2015.03.004

Cao S., 2015, Development of a LC–MS/MS method for the determination of dasatinib in rat plasma, Latin American Journal of Pharmacy, 34, 542

10.1155/2011/129045

10.1111/jphp.12270

Hamm C.(2013).ASH Annual Meeting Abstracts December 2013 Abstract 122:5216.

10.1016/j.jchromb.2009.04.045

10.12816/0013792

10.1016/j.cbi.2016.12.003

10.4037/ccn2002.22.2.22

10.1016/j.jchromb.2016.05.033

10.1016/j.jpba.2016.03.013

10.1016/j.jchromb.2017.02.029

10.1016/j.jpba.2017.01.039

10.1211/0022357011777819

10.1016/j.jep.2015.03.067

Miller J. N., 2000, Statistics and chemometrics for analytical chemistry

10.1002/bmc.2819

10.1371/journal.pone.0030604

10.1016/j.taap.2007.10.005

10.1016/j.jep.2006.07.021

10.1002/rcm.1767

10.1080/J157v05n01_09

10.1080/10496475.2013.871382

10.1002/rcm.1621

US Food and Drug Administration, Center for Drug Evaluation and Research, 2001, Guidance for industry on bioanalytical method validation

10.1016/S1470-2045(13)70579-5

10.1016/j.jep.2016.04.031

10.1016/j.ejca.2014.04.015

10.1016/j.gerinurse.2010.04.002

10.1093/chromsci/bmt037

10.1021/js980367q

Thông tin
Thông tin xuất bản

Biomedical Chromatography

Tập 33 Số 12

Thông tin tác giả